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Fluoroquinolone-
Resistant Group 
B Streptococci in 
Acute Exacerbation 
of Chronic 
Bronchitis 
To the Editor: Fluoroquinolones 
(FQs) that are active against strep-
tococcal species (e.g., levoﬂ  oxacin 
and moxiﬂ  oxacin) have been recom-
mended by numerous national health 
authorities and international organiza-
tions for treating acute exacerbations 
of chronic bronchitis and pneumonia 
in adults (1). However, use of these 
antimicrobial drugs for treating com-
munity-acquired infections has led to 
an increase in FQ-resistant strains in 
bacteria such as Streptococcus pneu-
moniae. Group B streptococci (GBS, 
e.g.,  S.  agalactiae) are the leading 
cause of invasive infections (pneumo-
nia, septicemia, and meningitis) in ne-
onates. GBS are also associated with 
bacteremia, endocarditis, and arthritis, 
and are responsible for deaths and ill-
ness in nonpregnant women with un-
derlying diseases and in elderly adults 
(2). We describe, to our knowledge, 
the ﬁ  rst GBS clinical isolate in France 
resistant to FQ; the isolate was from a 
patient treated with levoﬂ  oxacin. 
GBS CNR0717 strain was iso-
lated as the predominant bacterium 
in a culture (>107 CFU/mL) from 2 
purulent sputum samples from an 80-
year-old man (leukocytes >25, epithe-
lial cells <10) obtained 8 days apart. 
This patient was treated for 2 weeks 
with levoﬂ   oxacin, 750 mg/day, for 
acute exacerbation of chronic bron-
chitis. No other relevant respiratory 
bacterial pathogens were present in 
these samples. GBS CNR0717, a 
capsular serotype IV strain, was sus-
pected to have reduced susceptibil-
ity to FQs because no inhibition zone 
was observed around disks contain-
ing norﬂ  oxacin and peﬂ  oxacin disks, 
and reduced diameters were observed 
around disks containing ciproﬂ  oxacin 
and levoﬂ  oxacin. Antibiograms were 
performed according to recommen-
dations of the Clinical and Labora-
tory Standards Institute (3) on Mueller 
Hinton agar (Bio-Rad, Marnes la Co-
quette, France) supplemented with 5% 
horse blood. This strain was suscep-
tible to all other antimicrobial drugs 
usually active against GBS (penicillin, 
erythromycin, clindamycin, tetracy-
cline, rifampicin, vancomycin) and 
showed low-level resistance against 
aminoglycosides. MICs for 6 FQs 
(Table) indicate that GBS CNR0717 
was highly resistant to peﬂ  oxacin and 
norﬂ   oxacin, with MICs >64 mg/L, 
and showed increased MICs for cip-
roﬂ  oxacin, sparﬂ  oxacin, levoﬂ  oxacin, 
and moxiﬂ  oxacin. No reduction of FQ 
MICs was observed with reserpine (10 
mg/L), which indicated that resistance 
to FQ was not caused by an active ef-
ﬂ  ux pump system. 
Three major mutations have been 
reported for FQ resistance in strepto-
cocci at codon positions 81 in gyrA and 
79 or 83 in parC (4). DNA sequence 
analysis of these regions showed a 
mutation in parC (Ser 79 → Tyr) but 
not in the wild-type susceptible strain 
(NEM316). No mutation was detect-
ed in the gyrA gene. FQ resistance in 
streptococci is acquired through a step-
wise process and has been extensively 
studied in S. pneumoniae. First-step 
mutants conferring low-level resis-
tance generally result from mutations 
in either gyrA or parC. There is also 
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Table. MICs of fluoroquinolones for strains of group B streptococci (GBS), France 
MIC (mg/L)* 
Strain Pef Nor Cip Spa Lev Mox
G B S  C N R 0 7 0 1 7   > 6 4 > 6 4 4141
GBS NEM316  16 8 2 0.5 1 0.25
*Pef, pefloxacin; Nor, norfloxacin; Cip, ciprofloxacin; Spa, sparfloxacin; Lev, levofloxacin; Mox, 
moxifloxacin. 
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a molecule-dependent target speciﬁ  c-
ity: mutations in parC are generally 
selected by peﬂ  oxacin, ciproﬂ  oxacin, 
and levoﬂ  oxacin, and those in gyrA 
are selected by sparﬂ  oxacin, gatiﬂ  oxa-
cin, moxiﬂ  oxacin, gemiﬂ  oxacin, and 
garenoxacin (5). In second-step mu-
tants, mutations are present in both 
parC and gyrA and confer resistance 
to the antistreptococcal FQs levoﬂ  ox-
acin, moxiﬂ  oxacin, and gatiﬂ  oxacin. 
FQ resistance in GBS has been 
reported in Japan, the United States, 
and Spain (6–8). Up to now, all FQ-
resistant GBS strains described were 
highly resistant because of point muta-
tions in gyrA and parC QRDR; a parC 
mutation at position 79 was present 
in all strains. These strains were iso-
lated from elderly adults who, in some 
cases, had received quinolone therapy. 
Low-level resistance to FQ in GBS 
CNR0717 was associated with a Ser 
79 → Tyr mutation in parC. There-
fore, although the FQ sensitivity of 
this strain is unknown, a ﬁ  rst-step mu-
tant could have been selected in vivo 
as our patient was treated with levo-
ﬂ  oxacin for 2 weeks. 
GBS is an unusual cause of acute 
bacterial exacerbation of chronic bron-
chitis compared with other respiratory 
pathogens such as S. pneumoniae, but 
pathologies associated with this bacte-
rium are changing. Clinical microbiol-
ogists should be aware of these chang-
es and test isolates of Streptococcus 
spp. for susceptibility to FQs. This 
report indicates that FQ resistance 
among streptococci is a growing con-
cern and that levoﬂ  oxacin can select in 
vivo parC ﬁ  rst-step mutants that will 
facilitate emergence of high-level FQ-
resistant GBS strains, as demonstrated 
in vitro for S. pneumoniae (9). Finally, 
although FQ treatment is recommend-
ed for high-risk groups with acute 
exacerbations of chronic bronchitis, 
these antimicrobial drugs must be re-
served for situations in which there are 
no effective alternative drugs to treat 
infections caused by multidrug-resis-
tant bacteria. For susceptible strains, 
β-lactams, which still constitute the 
ﬁ  rst-line recommended antimicrobial 
drugs, should be used for treatment of 
these patients (10).
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Dengue and Relative 
Bradycardia
To the Editor: In a recent letter 
to Emerging Infectious Diseases, La-
teef and colleagues identiﬁ  ed a rela-
tionship between dengue and relative 
bradycardia in patients in Singapore. 
They stated that “To our knowledge, 
this sign has not been previously as-
sociated with dengue” (1). Unfortu-
nately, the association of dengue fever 
with relative bradycardia has already 
been well established and is certainly 
not a new ﬁ  nding (2,3). Despite this, 
however, there is no harm done in re-
inforcing an often forgotten clinical 
sign that can assist in the diagnosis of 
dengue, especially in those countries 
with limited resources.
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